Takeda, Baxter expand vax collaboration; J&J offers $2.3B for Crucell;

Vaccine Research 

> Takeda and Baxter "will expand upon their previously announced collaboration to bring Vero cell culture-based influenza vaccines to the Japanese market." Report

> The FDA has given Bavarian Nordic the green light to launch a late stage trial of its prostate cancer vaccine. Story

> In a research report presented in the December 2010 issue of the Journal of Leukocyte Biology, scientists from Singapore show that Mycobacterium chelonae, a common environmental bacterium found in soil and water, can decrease the effectiveness of the bacille Calmette-Guerin (BCG) vaccine used to prevent tuberculosis, especially in countries outside of the United States. Release

Vaccine Market

> J&J has formally offered $2.3 billion to acquire the Dutch vaccine maker Crucell. The two companies agreed on the buyout last October. If the deal proceeds as planned, J&J's vaccine gambit will qualify as its biggest acquisition in four years. Article

> Canadian health officials are calling for a national vaccination strategy, saying it's time to do away with the "patchwork" approach that has been in use. Story

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.